Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The North Carolina Utilities Commission issued written orders approving comprehensive revenue requirement settlements for Duke Energy Carolinas and Duke Energy Progress. The orders approve a 9.8% return on equity and retail rate bases totaling approximately $43.5 billion across both entities. Revised customer rates are expected to be implemented effective January 1, 2027.
Tonix Pharmaceuticals filed a patent infringement lawsuit against Dr. Reddy’s Laboratories in the U.S. District Court for the District of New Jersey following a Paragraph IV certification regarding TONMYA®. The filing of the complaint triggers a statutory 30-month stay of final FDA approval for Dr. Reddy’s proposed generic version of the drug. Tonix seeks to prevent generic competition until the expiration of its Orange Book-listed patents.
The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.
Skye Bioscience received a unanimous jury verdict in its favor following a retrial in the U.S. District Court for the Central District of California. The lawsuit, filed by a former employee, alleged whistleblower protection violations and retaliation related to events occurring between 2018 and 2019. The verdict clears the company of all claims, though the plaintiff retains the right to file post-trial motions or appeals.
Lamb Weston, Inc., a subsidiary of Lamb Weston Holdings, Inc., entered into a $25 million settlement agreement to resolve a putative class action lawsuit regarding groundwater nitrate levels in Oregon. The settlement fund will provide property enhancements and water filtration systems for residents, with payment expected in the second half of fiscal year 2027 subject to court approval.
Counterparty
Private plaintiffs in the U.S. District Court for the District of Oregon
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
KULR Technology Group filed a verified petition in the Delaware Court of Chancery under Section 205 of the DGCL to validate certain past corporate acts and its outstanding capitalization. The company identified technical failures in authorizing a 2016 name change, a 2018 increase in authorized common stock, and the designation of its Series A Preferred Stock, which it cannot ratify through standard procedures due to the disparate holding of putative shares.